William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.
Joe DiMasi
Advertisement
Articles by Joe DiMasi
Advertisement
Latest Updated Articles
Talkback from Tufts: Defending R&D CostsPublished: February 13th 2012 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences
3
GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate
4
ACS Calls Obesity a Condition That Must Be Treated with Medication and Surgery
5
